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Context: Lower TSH screening cutoffs have doubled the ascertainment of congenital hypothy-
roidism (CH), particularly cases with a eutopically located gland-in-situ (GIS). Although mutations
in knowndyshormonogenesis genesorTSHRunderlie some cases of CHwithGIS, systematic screen-
ing of these eight genes has not previously been undertaken.
Objective:Our objectivewas to evaluate the contribution andmolecular spectrumofmutations in
eight known causative genes (TG, TPO, DUOX2, DUOXA2, SLC5A5, SLC26A4, IYD, and TSHR) in CH
cases with GIS.
Patients, Design, andSetting:Wescreened49CH caseswithGIS from34ethnically diverse families,
using next-generation sequencing. Pathogenicity of novel mutations was assessed in silico.
Results: Twenty-nine cases harbored likely disease-causing mutations. Monogenic defects (19
cases) most commonly involved TG (12), TPO (four), DUOX2 (two), and TSHR (one). Ten cases
harbored triallelic (digenic) mutations: TG and TPO (one); SLC26A4 and TPO (three), and DUOX2
and TG (six cases). Novel variants overall included 15 TG, six TPO, and three DUOX2 mutations.
Genetic basis was not ascertained in 20 patients, including 14 familial cases.
Conclusions: The etiology of CHwith GIS remains elusive, with only 59%attributable tomutations
in TSHR or known dyshormonogenesis-associated genes in a cohort enriched for familial cases.
Biallelic TG or TPO mutations most commonly underlie severe CH. Triallelic defects are frequent,
mandating future segregation studies in larger kindreds to assess their contribution to variable
phenotype. A high proportion (41%) of unsolved or ambiguous cases suggests novel genetic
etiologies that remain to be elucidated. (J Clin Endocrinol Metab 101: 4521–4531, 2016)
Congenital hypothyroidism (CH) is the most commonneonatal endocrine disorder, and, historically, thy-
roid dysgenesiswas thought to account for approximately
80% of cases (1). However, recent studies have reported
a change in the epidemiology of CH, with a doubling in
incidence to around 1 in 1500 live newborns, predomi-
nantly driven by an increase in CH with eutopic gland-
in-situ (GIS), which accounted for almost two-thirds of
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
This article has been published under the terms of the Creative Commons Attribution
License (CC-BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source
are credited. Copyright for this article is retained by the author(s).
Received April 13, 2016. Accepted August 9, 2016.
First Published Online August 15, 2016
* A.K.N. and E.G.S. contributed equally to this work.
† Author Affiliations are shown at the bottom of the next page.
Abbreviations: ACHE, carboxy-terminal acetyl cholinesterase; CH, congenital hypothyroid-
ism; CNV, copy number variant; GIS, gland-in-situ; NGS, next-generation sequencing;
WES, whole exome sequencing.
O R I G I N A L A R T I C L E
doi: 10.1210/jc.2016-1879 J Clin Endocrinol Metab, December 2016, 101(12):4521–4531 press.endocrine.org/journal/jcem 4521
recently diagnosed cases in Lombardy, Italy (2). Lower
TSH screening cutoffs may be the major driver for this
increase in diagnosis, although altered ethnicities of the
screened population, increased multiple and premature
births, iodine status, and hitherto uncharacterized factors
may also contribute (3, 4).
The molecular basis of CH with GIS remains poorly un-
derstood (5, 6). Genetic variation in seven genes involved in
thyroid hormone biosynthesis (TG, TPO, DUOX2,
DUOXA2, IYD, SLC5A5, and SLC26A4) and TSHRme-
diates some cases. Disease-causingmutations are usually bi-
allelic,with the exceptionofmonoallelicDUOX2, IYD,and
TSHR mutations, which may also confer a phenotype (1).
Phenotypic heterogeneity in cases harboring similar caus-
ative mutations suggests that mono- and polygenic factors
and environmental modulators may also play a role in de-
termining disease severity (7, 8).
Genetic characterization of CHwith GIS has been lim-
ited by the cost and labor implications of Sanger sequenc-
ing multiple exons. Previous studies have generally fo-
cused on either a small number of genes (eg, TG, TPO,
TSHR, andDUOX2 in 43 Korean cases) (6), specific phe-
notypic subsets of cases (5, 8), or multiple genes in a small
subset of patients (9). There are occasional reports of di-
genic mutations involving TSHR and either DUOX2 (6,
10, 11) or TPO (12), or combined DUOX2 and
DUOXA2 mutations (13). However, the role of oligoge-
nicity in disease development and penetrance remains un-
clear, with no evidence for an additive effect of digenic
mutations in one large published kindred (12).
Next-generation sequencing (NGS) technologies in-
crease sequencing capacity and speed, enabling efficient
screening of multiple genes simultaneously. A recent pub-
lication describes large-scale multiplexed genetic screen-
ing of TPO, TSHR, DUOX2, DUOXA2, PAX8, and
SLC5A5 in 170 Korean CH cases. However, cases were
from a single ethnic background and not selected on the
basis of thyroid morphology; moreover TG, IYD, and
SLC26A4 were not sequenced (11). We undertook com-
prehensive screening of TG, TPO, DUOX2, DUOXA2,
IYD, SLC5A5, SLC26A4, andTSHR in an ethnically and
biochemically heterogeneous CH cohort with GIS. In ad-
dition to reporting known and novel mutations in these
genes, we document the frequent occurrence of potential
oligogenicity, with triallelic variation in two candidate
genes, in a population enriched for familial and consan-
guineous cases.
Patients and Methods
Patients
All investigationswere part of an ethically approved protocol
and/or clinically indicated, being undertaken with written in-
formed consent from patients and/or next of kin including spe-
cific consent for whole exome sequencing (WES) (MREC 98/5/
024). Forty-nine cases were included in the study from 34
families referred from centers in the United Kingdom, Oman,
Saudi Arabia, the United Arab Emirates, and Turkey. Inclusion
required clinical evidence of goiter or radiological evidence of a
normally sited thyroidgland in theproband. In five caseswithout
goiter who had not undergone thyroid imaging at diagnosis, we
accepted goiter or radiological evidence of GIS in at least one
affected family member with CH, assuming a common under-
lying genetic etiology.Adiagnosis of overt or subclinical primary
CHwasmadeon the basis of referral throughnewborn screening
and/or a raised venous TSH.Newborn screening blood spot cut-
offs were as follows: 6–10 mU/liter (United Kingdom), 10 mU/
liter (United Arab Emirates), or cord blood TSH 40 mU/liter
(Oman). Childhood TSH normal range was 0.35–5.5 mU/liter.
Thyroid biochemistry was measured using local analyzers in the
referring hospitals.
DNA sequencing
Three differentNGS-based strategies (whole-exome sequenc-
ing,WES, and two different targeted sequencing protocols) were
used to screenTG,TPO,TSHR,DUOX2,DUOXA2, IYD, NIS
(SLC5A5), and pendrin SLC26A4. Detailed methods, coverage,
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and quality control data are available in the SupplementalMeth-
ods andResults.We sought to identify rare variants (minor allele
frequency 0.02 in all control databases)with likely pathogenic
consequences predicted by in silico algorithms. Given the ethnic
heterogeneity of our cohort, we selected the maximum number
of control exomes (n  80, 000) matched as closely for eth-
nicity as we could achieve (Supplemental Methods). All positive
results were validated by Sanger sequencing.
Nomenclature
Variants were described using nomenclature approved by the
Human Genome Variation Society (http://www.HGVS.org/
varnomen). Further details are available in the Supplemental
Methods.
Structural model for TPO and DUOX2
The models for TPO and DUOX2 were generated using the
phyre2 (Protein Homology/analogy Recognition Engine 2) web
portal, which predicts and analyses protein structures based on
homology/analogy recognition to solved protein crystal struc-
tures (14). The figures were generated with MacPyMOL Mo-
lecular Graphics System, Schrödinger, LLC.
Results
Sequencing data quality
Detailed information regarding individual gene cover-
age is summarized in the (Supplemental Results). In the
samples sequenced byWES or HiSeq targeted sequencing
panel, optimal median coverage (30 fold) was achieved
for all genes exceptDUOXA2 and SLC5A5 in the eleven
samples screened by targeted sequencing (median cover-
age 5-fold and 24-fold respectively) (Supplemental Figure
1A, B). Exons screened using theMiSeq targeted sequenc-
ing panel either achieved amore than 20-fold coverage (in
house validation had demonstrated 100% sensitivity for
detecting variants at this sequencing depth), or were re-
peated by Sanger sequencing, such that this approach was
expected to be highly sensitive. In the WES and HiSeq
protocols, in common with previous studies employing
similar techniques, although median coverage was gener-
ally acceptable, coverage was nonuniform across individ-
ual genes (Supplemental Figure 2). This was most marked
with theHiSeq targeted sequencingpanel inwhich specific
exons exhibited a less than 10-fold coverage, including
DUOXA2 (exons 1, 2, 4, 5, and 6), SLC5A5 (exons 1–3,
5, 6, 11, 12, and 15), DUOX2 (exons 2, 5, 6, 8, 15, and
34), TG (exons 13, 15, and 16), TPO (exons 3, 7, 8, and
16), SLC26A4 (exon 21), and IYD (exon 6). A detailed
comparison of the sequencing techniques is provided in
Supplemental Figure 2.
Mutation frequencies (Figure 1)
Forty-nine cases from 34 families of European, Asian,
Middle Eastern, and Afro-Caribbean origin were investi-
gated and 29 cases (20 families, 59%) were considered
“solved” following identification of a decisive link be-
tween genotype and phenotype. In 11 “ambiguous” cases
(22%), it was felt that the ascertained genotype could
plausibly be contributing to the phenotype, but the evi-
dence to support a causal link was weaker than in the
“solved” group. Finally, nine cases were considered “un-
solved” because they carried no mutations in any of the
listed genes. Detailed genetic and phenotype data are sup-
plied in Supplemental Tables 1, 2, and 3.
CHwasmore severe biochemically in solved cases than
in unsolved or ambiguous cases (mean TSH, 100mU/liter
vs 36 mU/liter at diagnosis, P  .02, Welch’s t test) and
solved cases were more frequently from consanguineous
backgrounds (69% cases vs 40% cases). This likely re-
flects the increased incidence of recessive disease in the
presence of consanguinity because CH-associated muta-
tions in five of the eight targeted genes (TG, TPO,
DUOXA2, SLC5A5, and SLC26A4) are usually biallelic.
Cases with affected siblings were common in both solved
and unsolved or ambiguous categories (79% vs 70%
cases) (Figure 1, Supplemental Tables 2 and 3).
“Solved” kindreds harboring mutations in one
gene (monogenic kindreds)
Nineteen cases had a monogenic basis of disease, most
commonly involving biallelic mutations in TG (12 cases),
followed by TPO (four cases),DUOX2 (one monoallelic
and one biallelic mutation), and TSHR (one case). There
were no cases with CH attributable to mutations in IYD,
SLC5A5, or SLC26A4 (Figure 1).
TG mutations (Figure 2)
TG is the secretory protein upon which thyroid hor-
mone is synthesized, and the 12 cases withmonogenicTG
mutations predominantly exhibited moderate-severe CH
(Figure 2). One known and three novel homozygous non-
sense or frameshift mutations were identified which trun-
cate TG before the carboxy-terminal acetyl cholinesterase
(ACHE)-like domain, which has a crucial role in normal
conformational maturation and intracellular trafficking
of TG (F1, 2, 3, 4) (15). Two siblings (F5a, b) were com-
pound heterozygous for a known nonsense mutation
(p.R296*) and a rare, novel missense variant, (p.C160S)
that affects a highly conserved cysteine residue in TG
(Genomic Evolutionary Rate Profiling score 5.84). Cys-
teine residues within repetitive domains in the TG form
intramolecular disulphide bonds needed for protein fold-
ing; thus, p.C160S may be deleterious to TG affecting the
tertiary structure as predicted by PolyPhen (16–18). Two
siblings (F7a, b) harbored the samehomozygousTG splice
region variant (c.6385 GA) inherited from heterozy-
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gous parents; although the pathogenicity of this cannot be
ascertained in silico, it is unique to the affected siblings,
and adjacent to a known pathogenic mutation
(c.6381GA) (19), supporting causality, albeit in asso-
ciation with a mild CH phenotype.
TPO mutations (Figure 3)
TPO is the heme peroxidase catalyzing the final steps of
thyroid hormone synthesis, and biallelic mutations (Fig-
ure 3) were identified in four monogenic kindreds. These
included twoknownpathogenicmissensemutations (F16;
p.R491H, F17; p.R665Q), two novel frame shift (F20;
p.C808Afs*24, F16; p.A397Pfs*76), and two novel mis-
sense variants (F18; p.R291H, p.G331V) (Table 2). The
p.R291H variant is predicted to disrupt a hydrogen bond
network close to the TPO heme group thereby destabiliz-
ing the catalytic domain. G331 is located close to the sub-
strate binding domain, and mutation to the larger valine
aminoacidwill likely cause steric hindrance impeding sub-
strate binding (Figure 3). Two cases were compound
heterozygous: F16 p.[A397Pfs*76];[R491H], associated
with dyshormonogenic goiter requiring thyroidectomy,
and F18 p.[R291H];[G331V], who also exhibited goiter.
DUOX2 mutations (Figure 4)
DUOX2 is the nicotinamide adenine dinucleotide
phosphate oxidase, which generates H2O2 required for
thyroid hormone biosynthesis. Two solved cases with
monogenicDUOX2mutationswere identified (Figure 4),
including one known heterozygous mutation (F23;
p.F966Sfs*29) andonenovel homozygousmutation (F24;
p.L1028Afs*3), both of which would truncate DUOX2
before the nicotinamide adenine dinucleotide phosphate
oxidase domain, thereby abrogating protein function. Af-
fected cases generally had a milder or transient (F23) CH
phenotype comparedwith cases harboringmonogenicTG
and TPO mutations.
Figure 1. Schematic illustrating case selection, variant filtering, and distribution of mutations in the cohort of patients studied with CH and GIS.
“Solved” cases refers to cases in whom a definitive link was established between genotype and CH phenotype. In “ambiguous” cases, the
ascertained genotype could plausibly be contributing to the phenotype, but the evidence to support a causal link was weaker than in the “solved”
group, and “unsolved” cases carried no mutations in any of the listed genes. The numbers of cases harboring monoallelic or biallelic mutations in
each gene are listed beneath the corresponding gene name for the “solved” cases. Numbers in the intersect between circles denote triallelic cases
harboring mutations in both genes. In the “ambiguous” category, the number of mutations in each gene is classified by mutation type beneath
the relevant gene name; all except DUOXA2 were monoallelic. “Solved” and “ambiguous” or “unsolved” cases were equally likely to be familial,
but CH was generally more severe in the “solved” cases. fs*; frameshift mutation resulting in a premature stop codon; MAF, minor allele
frequency; splice; splice region variant, VUS, variant of uncertain significance.
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TSHR mutation
A single individual from theUnitedArab Emirateswith
mild CH harbored a known pathogenic heterozygous
TSHR mutation (F26; p.P68S) (Supplemental Table 2),
previously identified in an Arab population. Parental
DNAwas not available; however, themild CHphenotype
was consistent with previously reported biochemistry as-
sociated with this mutation (20).
“Solved” kindreds harboring mutations in two
genes (oligogenic kindreds, Figure 5)
Ten solved cases from seven families harbored digenic
pathogenic variants. These were predominantly triallelic,
and most commonly comprised biallelic TGmutations in
association with a monoallelic DUOX2 mutation. Such
digenic mutations were detected in consanguineous Turk-
ish kindreds F6, 8, and 9 (Figure 5). In these kindreds,
although defined as variants of uncertain significance by
ACMG criteria, the biallelic TG mutations were rare (p.
W1051L;MAF0.001 in 1KG Europeans, and absent in
all other population datasets, including ExAC East
Asians) or unique, affected conserved amino acids and
were predicted to be pathogenic by PolyPhen and SIFT. In
F6, two siblings (a, b)withCHwere both homozygous for
TG p.W1051L and p.C726Y but one sibling (F6b) har-
bored an additional, maternally inherited heterozygous
DUOX2mutation (p.Q686*), previously described in as-
sociation with transient CH (21). Biochemistry at diag-
nosis could not be retrieved fromF6b for comparisonwith
F6a; however, both presented with neonatal goiter and
had similar levothyroxine requirements. Their mother ex-
hibited adult-onset hypothyroidism of unknown etiology.
Two unrelated sibling pairs also harbored homozygous
TG mutations in association with a heterozygous
DUOX2 mutation: TG p.1493Y and DUOX2 p.Q686*
in F8a, b and TG p.W2685L and DUOX2 R354W (pre-
dicted to perturb the DUOX2 peroxidase-like domain) in
F9a, b (Figure 4). There was also a strong history of goiter
(mother and maternal aunt) in F8 but maternal DNAwas
not available to confirm DUOX2 genotype. In all three
kindreds, the most severe phenotype was observed in in-
dividuals harboring biallelic TG or triallelic (biallelic TG
andmonoallelicDUOX2) mutations; however, it was im-
Figure 2. Summary of TG mutations identified in the study and the associated biochemical phenotype. CH severity is classified according to
European Society for Paediatric Endocrinology criteria on the basis of serum fT4 levels; severe, 5, moderate 5 to 10, and mild 10 pmol/liter,
respectively (33) and pathogenicity is predicted according to American College of Medical Genetics guidelines (34). A schematic of the TG protein
illustrates the position of the mutations relative to the key structural domains of TG including the repetitive type 1, 2, and 3 cysteine-rich regions,
acetylcholinesterase homology (ACHE-like) domain and hormonogenic domains. Known mutations are shown in gray, novel mutations in black.
*Cases for which complete biochemical data at diagnosis is not available. CH severity refers to sibling. bs, blood spot.
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possible to distinguish the effects of the mutations in the
two genes reliably in these small pedigrees with limited
subphenotype data.
Since monogenic, heterozygous DUOX2 mutations
(including p.Q686*) are frequently associated with CH,
we hypothesized that an additive phenotypic contribution
of all three mutations was very plausible. Calculation of
the number of East Asian individuals in the ExAC data-
base (n 8654) harboring similarly rare, predicted dam-
aging variants inDUOX2 yielded a population mutation
frequency of 0.06%. The observed proportion of TGmu-
tation carriers with a monoallelicDUOX2 variant in our
cohort (8.8% families) was therefore significantly higher
(P  .0233, Fisher’s exact one-tailed test), supporting a
potential phenotypic contribution of the DUOX2 muta-
tion in these individuals. Much larger cohorts of se-
quencedCH individuals will be required to assess the phe-
notypic consequences of digenicity in CH thoroughly.
Biallelic mutations in TPO were identified in two kin-
dreds in addition to heterozygous known SLC26A4 mu-
tations, previously associatedwith recessivedisease: F19a:
TPO p.R584Q (homozygous) and SLC26A4 p.N324Y
(heterozygous); F19b: TPO p.R584Q (homozygous)
and SLC26A4 p.I713M (heterozygous); F21: TPO
p.[E17Dfs*77]; [Y453D] (compound heterozygous); and
SLC26A4 p.E384G (heterozygous) (Figure 5). The novel
TPO p.R584Q missense variant is predicted to perturb
polar contacts possibly affecting the catalytic domain
(Figure 4).
The occurrence of Pendred syndromeusuallymandates
biallelic SLC26A4 mutations, and manifests universally
with congenital or postnatal progressive sensorineural
hearing loss, whereas thyroid dysfunction is usually mild
or absent. In both these kindreds, only the biallelic TPO
mutations segregated with CH; this was severe whereas
hearingwas normal. In F11, a known homozygous patho-
genic TPO mutation (p.R491H) was inherited together
with a heterozygous TG variant (p.Q1644E). Because bi-
Figure 3. Summary of TPO mutations identified in the study and the associated biochemical phenotype. CH severity is classified according to
European Society for Paediatric Endocrinology criteria (33) and pathogenicity is predicted according to American College of Medical Genetics
guidelines (34). The effect of the novel missense mutations was modeled using the phyre2-server. Figures in the top row show the wild-type (WT)
model, with amino acids of interest in green; figures on bottom row show the model with the mutant amino acid (orange); local polar contacts are
shown with black broken lines. The R291H and R584Q mutations affect amino acids contributing to an intensive network of H-bond contacts
close to the catalytic domain involving the heme-group. R291 makes polar contacts with R585 and R582, interacting directly with the heme-group
and R584 makes direct polar contacts with the heme-group itself as well as P203 and D633. The mutations R291H (increased hydrophobicity) and
R584Q (resulting in a smaller polar group) are likely to disrupt polar contacts affecting local structure and are predicted to affect catalytic activity.
The G331V mutation affects local space filling with the larger valine predicted to impair substrate binding by displacement of the nearby helix and/
or disruption of polar contacts (orange amino acids, H2O molecules in blue), affecting the local structure of TPO.
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allelic inheritance is also usually required for CH due to
TG mutations, these observations suggest the TPO mu-
tations are predominant drivers of the CH phenotype in
these three kindreds, although we cannot definitively ex-
clude a contribution of the heterozygous SLC26A4 orTG
mutation. Comparison with population mutation fre-
quencies in TG and SLC26A4 in the ExAC cohort (non-
Finnish Europeans, N  66,740), suggested that congru-
ence of TPO mutations with TG or SLC26A4 mutations
was not increased in our cohort (P  .2280, P  .0951
respectively).
Detailed investigation of the contribution of oligoge-
nicity to genotype-phenotype variability mandates the
study of large kindreds with a spectrum of genotypes, eg,
F10 (Figure 5). In this large, consanguineous Pakistani
kindred, the proband harbors a known pathogenic
DUOX2mutation (p.Q570L, previously published in ref.
8). Homozygosity for this mutation segregates with per-
manent CH (F10a), whereasDUOX2 p.Q570L heterozy-
gotes exhibit either euthyroidism or transient CH. Two
novel, rareTGvariants (p.L2547Q,predicted tobepatho-
genic byPolyPhenandSIFT, andp.R1691C,of less certain
significance) were also identified in this kindred, yet nei-
ther of these variants segregated with transient CH in the
DUOX2 p.Q570L heterozygotes, suggesting digenic mu-
tations in the genes screened did not explain the pheno-
typic variability associated with this genotype.
Unsolved or ambiguous kindreds (Figure 1,
Supplemental Table 3)
This group included two cases harboring heterozygous
pathogenicTGvariants; a novel nonsensemutation inF13
(p.Q771*) and a previously described missense mutation
in F12 (p.Q870H). An additional case was heterozygous
for a frameshift mutation in TPO (p.E510Afs*14, F22).
Previous reports of CH due to TG and TPO mutations
most commonly involve biallelicmutations; therefore, it is
unclear whether the mild or subclinical hypothyroidism
was attributable to the monoallelic mutation or whether
they harbored a second “hit” not detected by our sequenc-
ing methods. Other cases in this category harbored novel
heterozygous TG missense (p.Y759C, F14) or splice re-
Figure 4. Summary of DUOX2 mutations identified in the study and the associated biochemical phenotype. CH severity is classified according to
European Society for Paediatric Endocrinology criteria (33) and pathogenicity is predicted according to American College of Medical Genetics
guidelines (34). Mutation position is illustrated using a schematic representation of the domain structure of the DUOX2 protein. Known mutations
are shown in gray and novel mutations in black. The structural model of the peroxidase domain suggests that R354 is part of an intensive
hydrogen network. The novel missense mutation R354W replaces the hydrophilic arginine by the hydrophobic tryptophan disrupting this network
and also results in a possible repositioning of the loop containing R354 and C351, which mediates interactions between the peroxidase domain
and extracellular loops obligatory for DUOX2 function.
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gion (c.34333_34336delGAGT, F15) variants, a
novel heterozygousDUOX2 variant (p.R764W, F25) in-
herited from a healthy parent and a homozygous
DUOXA2 splice site (c.555–5GA) variant for which in
silico predictions were inconclusive (F27). Nine cases
(seven families) remained completely unsolved with no
likely disease-causing variants identified. Copy number
variant (CNV) analysis was undertaken in individuals
who had undergonewhole exome sequencing: F13, 15, 33
(ambiguous or unsolved cases) and F3, 6–10 (solved cas-
es); however, no rare CNVs were identified that segre-
gated with disease phenotype in each pedigree.
Discussion
In this study,NGS technologies enabled efficient screening
of eight genes associatedwithCHandGIS in49 cases from
the United Kingdom, Turkey, Middle East, and Asia, and
with a spectrumof biochemical phenotypes. In addition to
single-genemutations, the contribution of oligogenic vari-
ants was assessed. Previous genetic evaluations of cohorts
of CH with GIS have been less comprehensive, screening
fewer genes, or fewer caseswith restricted ethnicities (6, 9,
22, 23).Theonly large-scalemultiplex study inCHdidnot
select caseson thebasis of thyroidmorphologyandexcluded
TG, SLC26A4, and IYD from its sequencing panel (11).
Direct sequencing of DUOX2, TG, TPO, and TSHR has
been undertaken in 43 Korean CH cases with GIS (6); in
commonwithourstudy,onlyaround50%ofcasesharbored
causative, pathogenic variants in one or more genes.
The relative frequencyofmutations inknownCHcaus-
ative genes depends on selection criteria and ethnic origin
of the cohort (6, 24). Our cohort included individuals of
diverse ethnicities, in whom the biochemical diagnosis of
CHwas achieved using different, country-specific, screen-
ing protocols, or following neonatal or early childhood
presentationwith clinical hypothyroidism.Thesemultiple
variables preclude detailed comparison of relative muta-
tion frequencies with other studies of populations with
more uniform ethnicity or biochemical diagnostic ap-
proach. The heterogeneous population screened in this
study also mandated the use of ethnically matched con-
Figure 5. Genotype-phenotype segregation in six kindreds with oligogenic variants. Horizontal bars denote individuals who have been
genotyped. Black shading denotes homozygous individuals and half-black shading denotes heterozygotes for TG mutations (F9, F6, F8), TPO
mutations (F19, F21), and DUOX2 mutations (F10). Potential oligogenic modulators are included by aligning genotype and phenotype data with
the individual to whom they refer in the pedigree. *Cases for whom complete biochemical data at diagnosis are not available (F6b, F8a); CH
severity refers to sibling. In F10, black, half-black, and white shading denote the DUOX2 genotype (Q570L homozygous, heterozygous, or wild-
type, respectively). The pedigree is annotated with TG genotype in those cases harboring variants (L2547Q, R1691C), and phenotype (euthyroid,
transient, or permanent CH) with venous screening TSH results for CH cases. Cases annotated (euthyroid) were born in Pakistan and although
euthyroid in adulthood; that they were not screened neonatally for CH may have precluded detection of transient CH.
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trols in order to prevent “false-positive results” due to
incorrect classification of ethnically specific single nucle-
otide polymorphisms as pathogenic mutations. The pau-
city of West Asian exomes in publically accessible data-
bases precluded this for 17 non-TurkishWest Asian cases.
However, the large number of controls used (80,000)
and that eight of the 10 solvedWest Asian cases harbored
truncating or previously reported CH-associated muta-
tions, made false-positive results unlikely.
In our study, mutations were most frequently found in
TG, followed by TPO, whereasDUOX2mutations were
relatively infrequent compared with findings by Jin et al
(mutations in 35% all cases), probably reflecting the
higher prevalence ofDUOX2mutations in individuals of
East Asian ethnicity, who were poorly represented in our
study (6, 11, 25). No definitively pathogenic mutations
were found in DUOXA2, IYD, or SLC5A5, which is in
keeping with previous reports suggesting that these are
rare genetic causes of dyshormonogenesis, with the ex-
ceptionof a recurrentDUOXA2mutation inKoreancases
(26, 11). The paucity of TSHRmutations in a CH cohort
withGIS is surprising; however, the high incidence of con-
sanguinity in our cohort predicts occurrence of biallelic
mutations that, in the case of TSHR, may cause thyroid
hypoplasia, with such cases possibly being excluded from
recruitment to our GIS CH cohort (6, 27). Despite unse-
lected recruitment of either sporadic or familial cases, our
cohort was greatly enriched for familial CH (76% cases),
and consanguinity,whichmayhave increased the percent-
age of cases harboring an underlying genetic etiology. In a
standardUnitedKingdom clinic populationwith a greater
proportion of sporadic, nonconsanguineous cases, the
proportion of mutation-negative cases could be higher.
Interpretation of novel genetic variants requires func-
tional studies in vitro or in vivo evidence of impaired TSH-
stimulated mutant thyroglobulin production for TG muta-
tions) to confirmpathogenicity (18).Although suchanalyses
were not undertaken, the novel variants identified are rare,
segregate with phenotype, and have strong bioinformatic or
structural (TPO) predictions of pathogenicity, supporting a
causal role.Moreover, the location of novel variants inTPO
(heme-binding region or substrate-binding region) and
DUOX2 (R354W; peroxidase-like domain) mirrors that of
previously described pathogenic mutations. Analysis of
novelvariants inTG ishinderedbyanincompleteknowledge
of its functional domains or crystal structure, but those iden-
tified affect similar regions to previously documentedmuta-
tions (N-terminal cysteine-rich repetitive elements, C-terminal
ACHE-like domain) also supporting causality (8, 16, 18, 28).
The associated clinical phenotypes in our mutation-
positive patients were similar to published cases. TGmu-
tations may result in euthyroid goiter and mild or severe
hypothyroidism (18), and monoallelic and biallelic
DUOX2 mutations may both cause permanent or tran-
sient CH (8, 21, 23, 25). Even TPO mutations, although
classically associated with total iodide organification de-
fects, can cause milder phenotypes (28). Solved cases usu-
ally had a more severe phenotype than unsolved or am-
biguous cases; however, the latter group included four
cases of subclinical or mild CH harboring heterozygous
mutations in TPO or TG. Such monoallelic mutations
have previously been described in association with CH,
but are usually assumed to coexist with an additional un-
detected CNV, intronic, or regulatory mutation on the
other chromosome (16, 24, 29). This may be the case in
our patients as well; our sequencing techniques would not
have detected mutations in noncoding regions of the ge-
nome and, although CNVs were not detected in F15, 13,
and 33, they could not be excluded in the remaining fam-
ilies.Our observations highlight thatmutations inTPOor
TG may underlie subclinical hypothyroidism as well as
cases with overt CH. Despite elevated TSH levels, several
of our non-TSHR mutation-positive cases (mainly de-
tected in theneonatal period) didnot exhibit goiter.Quan-
titationof thyroid volume radiologically at this age is tech-
nically challenging, such that mild thyroid enlargement
may not have been detected. However, TSH-driven goi-
trogenesis in these cases will have been dependent on fetal
TSH levels—whose role in thyroid follicular cell growth
remains unclear. In common with our findings, others
have demonstrated that dyshormonogenetic CH, even as-
sociated with total iodide organification defect, is not al-
ways associated with thyroid enlargement (30).
Oligogenicity has often been proposed to underlie the
intrafamilial variability seen in known genetic causes of
CH, especially in associationwithDUOX2mutations (8).
ThePax8/Titf1murinemodel exemplifies the role of poly-
genicity in thyroid dysgenesis because only mice doubly
heterozygous for the two null alleles and bred on a
C57BL/6 background exhibit a phenotype (31). Despite
reports of digenicGIS cases in the literature, pedigree stud-
ies have either not been performed (11, 6) or have not
confirmed a genotype-phenotype correlation (12). Our
study detected likely pathogenic variants inmore than one
CH-associated gene, especially in consanguineous kin-
dreds, most commonly involving TG and DUOX2. It is
possible that this is a conservative estimate of the fre-
quency of oligogenicity in CHwith GIS; the high percent-
age of consanguinity in our study facilitates identification
of potentially pathogenic variants in a disease model with
recessive inheritance, but also increases the likelihood of
detecting variants which are contributory to the CH phe-
notypebutnot causative, due to theoccurrenceof genomic
regions with loss of heterozygosity involving CH-associ-
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ated genes. Accordingly, we cannot discount the possibility
that some of our monogenic, consanguineous, “solved”
cases harbor additional mutations in genes that were not
screened in our study, which could contribute to the CH
phenotype. Small pedigree sizes, poor information about
mutation frequencies in populations matched to our CH
cases,andapaucityof subphenotypedataprecludedefinitive
statements regarding the relative etiological contribution of
digenicity in CH. Further studies with large pedigrees and
clear phenotypic variability are required to ascertain the role
of polygenic modulators in CH with GIS. Alternative can-
didate genes involved in the same biological pathways as
known causative genesmay be implicated, either exacerbat-
ing or playing a compensatory role in the context of loss-of-
functionmutations.Examples includeDUOX1,DUOXA1,
andNOX, which are also involved inH2O2 production and
whose expression may be upregulated in the context of
DUOX2 deficiency (12, 32).
It is conceivable that despite adequate median cover-
age, nonuniform coverage of genes could have resulted in
failure to detect variants. This is most likely to be signif-
icant for the 11 cases (eight families) in which coverage of
specific exons was less than 10-fold (predominantly af-
fectingDUOXA2 and SLC5A5). Suboptimal coverage of
these regions raises the possibility of a type II error. How-
ever, undetected variants in these cases are unlikely to
affect the conclusions of this study because five cases har-
bored mutations that explained their CH (F26, F2a, b,
F11, F17), and two ambiguous cases harbored heterozy-
gous TG variants (F12 a, b). Additionally, although the
study was not designed to allow direct comparison of dif-
ferent sequencingmethods, the rateof causativemutations
in cases screened using either the most sensitive technique
(MiSeq targeted sequencing, in which exons with 20-
fold coverage were individually resequenced using Sanger
sequencing) or WES, was similar and supported our con-
clusion that approximately 40% cases are unsolved. Pre-
vious studies have also reported considerable variability in
uniformity and depth of coverage across the exome, and
these data, together with our sequencing depth analysis,
highlight a limitation of targeted sequencing, which may
impact and limit variant identification (33). High-depth,
whole-genome sequencing can improve exon coverage
and the advent of recent sequencing technologies (such as
the IlluminaX10system)makes thispossible at large scale.
The etiology of CH with GIS remains elusive, and fac-
tors other than known dyshormonogenesis-associated
genes or the TSHRmust be implicated. CHwith GIS may
be transient, and most of our cases did not undergo a
formal trial off levothyroxine withdrawal. However, re-
quirement for ongoing levothyroxine replacement in sig-
nificant dosage, or continuing TSH elevation, suggested
persistent CH in at least 12 unsolved cases. Biochemical
CH did tend to be more severe in genetically ascertained
cases, which argues against the routine screening of TG
and TPO in milder GIS CH cases. Iodine status was not
assessed; however, the high familial component in the un-
solved case category favors an etiological contribution of
genetic factors rather than environmental modulators, in-
cluding regulatory region or intronic mutations, or CNVs
in the genes screened. Genes associated with syndromic
CH (eg,GLIS3, GNAS) were not analyzed. Not formally
quantitating thyroid gland size might have failed to ascer-
tain cases with mild thyroid hypoplasia, harboring muta-
tions in some thyroid-dysgenesis associated genes (eg,
PAX8, Nkx2–1). Our aim in using the HiSeq-targeted
sequencing and MiSeq protocols was to exclude muta-
tions in known CH-associated genes to identify a smaller,
mutation-negative cohort, which could then be analyzed
by WES. Thus, future studies with WES/whole genome
sequencing in familial cases may identify novel genetic
etiologies for CHwith GIS, elucidating novel pathways in
thyroid development and physiology.
Note added in proof:During preparation and revision of
thispaper, twoofthevariantswhichwedefinedasnovelhave
been described by other groups in association with congen-
ital hypothyroidism: TG c.6385G>A (Li Y, Salfelder A,
Schwab KO, et al. Against all odds: blended phenotypes of
three single-gene defects.Eur JHumGenet. 2016;24:1274–
1279) andDUOX2 c.1060C>T, R354W (Liu S, ZhangW,
Zhang L, et al; Genetic and functional analysis of two mis-
sense DUOX2mutations in congenital hypothyroidism and
goiter.Oncotarget. 2016 doi:10.18632/oncotarget.10525).
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